Skip to main content

Connective tissue diseases


Browse the latest news, expert commentary, and educational content on connective tissue diseases.


Highlights

Doctor holding virtual heart in hand. - healthcare concept

07-12-2022 | Rheumatoid arthritis | News

Similar reduction in CV risk with different add-on RA treatments

Among patients with active rheumatoid arthritis, adding tumor necrosis factor inhibitors to methotrexate is associated with a similar reduction in vascular inflammation to that seen with add-on sulfasalazine plus hydroxychloroquine, suggest findings from a randomized controlled trial.

Simple 3d scene representing arrows, that hit targets with blackvision - target concept

28-11-2022 | Rheumatoid arthritis | News

Treatment goals in late-onset RA should match those for younger patients

People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same in both populations, researchers report.

Debate (concept)

18-11-2022 | ACR 2022 | Conference coverage | News

A Great Debate: To treat or not to treat in pre-RA?

In one of two Great Debate sessions at ACR Convergence 2022 in Philadelphia, Pennsylvania, USA, two experts teamed up to provide opposing stands on whether now is the right time to be treating people at risk for rheumatoid arthritis in the preclinical stages of the condition in order to prevent disease onset.

Rheumatoid arthritis

07-12-2022 | Rheumatoid arthritis | News

Similar reduction in CV risk with different add-on RA treatments

Among patients with active rheumatoid arthritis, adding tumor necrosis factor inhibitors to methotrexate is associated with a similar reduction in vascular inflammation to that seen with add-on sulfasalazine plus hydroxychloroquine, suggest findings from a randomized controlled trial.

28-11-2022 | Rheumatoid arthritis | News

Treatment goals in late-onset RA should match those for younger patients

People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same in both populations, researchers report.

18-11-2022 | ACR 2022 | Conference coverage | News

A Great Debate: To treat or not to treat in pre-RA?

In one of two Great Debate sessions at ACR Convergence 2022 in Philadelphia, Pennsylvania, USA, two experts teamed up to provide opposing stands on whether now is the right time to be treating people at risk for rheumatoid arthritis in the preclinical stages of the condition in order to prevent disease onset.

Lupus

19-12-2022 | Systemic lupus erythematosus | News

Anti-dsDNA antibodies have potential to guide targeted therapy use in SLE

An exploratory analysis of data from the phase 2b BEAT LUPUS trial suggests that IgA2 anti-dsDNA antibody levels may be able to predict response to B cell-targeted therapies in patients with systemic lupus erythematosus.

14-11-2022 | ACR 2022 | Conference coverage | News

Phase 3 trial supports add-on telitacicept for SLE

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.

10-11-2022 | Systemic lupus erythematosus | News

Achieving LLDAS tied to reduced mortality risk in SLE

Achievement of LLDAS is associated with a significant reduction in mortality risk among people with systemic lupus erythematosus, study findings suggest.